ImmunityBio, Inc. (IBRX) Stock Profile & Financial OverviewImmunityBio, Inc.
IBRX Company Overview & Business Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Key Information
Current Trend for IBRX
An assessment of the current trend environment for IBRX, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for IBRX is a Sideways Consolidation (Range-Bound Environment).
The weekly trend is in a consolidation regime, which automatically downgrades the daily signal to sideways conditions. This environment favors short-term mean-reversion rather than trend-following.
- The weekly context is non-trending (sideways), which typically caps the duration and magnitude of daily trend moves.
- Price is currently trending at a healthy distance, sitting -1.00 ATR away from the adaptive KAMA baseline.
- The current market structure is holding within recent defined ranges.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, IBRX in a non-directional consolidation; Long-term trend is bullish.
Trend Strength: IBRX last closed at 2.14, trading 0.5 ATR below the adaptive KAMA baseline (2.21). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Risk indicators: No active structural constraints identified.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 2.14, KAMA 2.21.